Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Phase 3 Study in Japan (jRCT2080223648)
jRCT2080223648Phase 3Completed
- Start
- Sep 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3 trial of pembrolizumab in cancer (2 arms). Started Sep 2017; status: completed.
02
Drugs
03
Conditions
cancer
Beyond the preview
Go deeper on jRCT2080223648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223648.